Philippe Moreau Selected Research

isatuximab

10/2022	Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
10/2022	Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
6/2022	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
5/2022	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
1/2022	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
1/2022	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
1/2022	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
12/2021	A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
11/2021	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
1/2021	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Moreau Research Topics

Disease

279	Multiple Myeloma 10/2022 - 01/2002
65	Neoplasms (Cancer) 05/2022 - 01/2003
31	Disease Progression 10/2022 - 11/2005
18	Infections 01/2021 - 12/2005
17	Thrombocytopenia (Thrombopenia) 01/2022 - 04/2013
17	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 08/2009
16	Neutropenia 01/2022 - 08/2009
12	Residual Neoplasm 01/2022 - 11/2012
10	Pneumonia (Pneumonitis) 01/2022 - 10/2013
8	Hematologic Neoplasms (Hematological Malignancy) 10/2021 - 12/2004
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 08/2003
8	Inflammation (Inflammations) 01/2021 - 02/2003
8	Melanoma (Melanoma, Malignant) 01/2018 - 10/2003
7	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 10/2010
7	Lymphopenia (Lymphocytopenia) 11/2021 - 10/2014
7	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2021 - 01/2010
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2016 - 11/2005
7	Hypoxia (Hypoxemia) 09/2016 - 04/2007
6	Lymphoma (Lymphomas) 10/2021 - 03/2002
6	Malaria 01/2021 - 06/2013
6	Fatigue 01/2020 - 10/2013
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 03/2002
6	Virus Diseases (Viral Diseases) 01/2017 - 01/2003
5	Sepsis (Septicemia) 01/2022 - 12/2009
5	Immunoglobulin Light-chain Amyloidosis 10/2020 - 11/2004
5	Smoldering Multiple Myeloma 05/2020 - 10/2017
5	Choriocarcinoma 10/2019 - 11/2003
4	Septic Shock (Toxic Shock Syndrome) 10/2021 - 09/2012
4	Hypertension (High Blood Pressure) 10/2021 - 01/2016
4	Pain (Aches) 01/2021 - 04/2008
4	Monoclonal Gammopathy of Undetermined Significance 01/2021 - 01/2017
4	Vomiting 08/2020 - 03/2012
4	Leukemia 01/2019 - 07/2012
4	Anemia 01/2019 - 10/2016
3	Bone Diseases (Bone Disease) 01/2022 - 03/2014
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021 - 01/2019
3	Diarrhea 08/2020 - 03/2017
3	Nausea 08/2020 - 03/2012
3	Febrile Neutropenia 05/2020 - 04/2013
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2019 - 09/2014
3	Bronchiolitis Obliterans Syndrome 11/2017 - 09/2005
3	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 02/2013
2	Body Weight (Weight, Body) 11/2022 - 12/2004
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 12/2019

Drug/Important Bio-Agent (IBA)

123	Dexamethasone (Maxidex)FDA LinkGeneric 10/2022 - 11/2006
73	Bortezomib (Velcade)FDA Link 01/2022 - 11/2006
66	Lenalidomide (CC 5013)FDA Link 01/2022 - 05/2008
46	HLA-G Antigens (HLA G)IBA 05/2021 - 01/2003
35	carfilzomibIBA 10/2022 - 04/2014
30	daratumumabIBA 10/2022 - 06/2016
29	Proteasome InhibitorsIBA 01/2022 - 08/2012
29	pomalidomideIBA 01/2022 - 03/2013
25	Thalidomide (Thalomid)FDA Link 10/2021 - 01/2002
22	Monoclonal AntibodiesIBA 06/2022 - 09/2007
20	ixazomibIBA 01/2022 - 08/2014
19	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 02/2002
16	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2005
13	isatuximabIBA 10/2022 - 12/2019
12	Pharmaceutical PreparationsIBA 01/2022 - 02/2010
11	PanobinostatIBA 01/2021 - 07/2013
11	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 11/2005
9	Immunomodulating AgentsIBA 01/2022 - 07/2013
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2021 - 02/2015
7	venetoclaxIBA 11/2021 - 04/2015
7	Immunoglobulins (Immunoglobulin)IBA 05/2020 - 12/2014
7	elotuzumabIBA 01/2019 - 06/2012
6	Prednisone (Sone)FDA LinkGeneric 01/2019 - 11/2008
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2018
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 11/2009
5	selinexorIBA 01/2022 - 01/2019
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 07/2009
5	CytokinesIBA 01/2021 - 10/2003
5	Biological ProductsIBA 08/2019 - 09/2002
4	B-Cell Maturation AntigenIBA 01/2022 - 01/2020
4	Histone Deacetylase InhibitorsIBA 01/2018 - 07/2013
4	3' Untranslated Regions (3' UTR)IBA 01/2017 - 06/2013
4	Messenger RNA (mRNA)IBA 09/2016 - 10/2005
3	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2015
3	AntigensIBA 01/2019 - 11/2005
3	Clofarabine (Clolar)FDA Link 01/2019 - 01/2017
3	LuciferasesIBA 01/2018 - 09/2013
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2018 - 07/2014
3	Immunoglobulin G (IgG)IBA 10/2017 - 09/2013
3	Alkylating AgentsIBA 01/2017 - 02/2010
3	Transcription Factors (Transcription Factor)IBA 01/2017 - 04/2007
3	Bendamustine Hydrochloride FDA Link 02/2015 - 02/2010
2	VaccinesIBA 05/2022 - 12/2021
2	AntibodiesIBA 05/2022 - 01/2021

Therapy/Procedure

111	Therapeutics 10/2022 - 01/2002
59	Stem Cell Transplantation 01/2022 - 02/2002
22	Transplantation 01/2022 - 05/2008
22	Drug Therapy (Chemotherapy) 12/2021 - 09/2002
9	Hematopoietic Stem Cell Transplantation 05/2022 - 12/2004
5	Autologous Transplantation 01/2014 - 11/2008
4	Subcutaneous Injections 11/2022 - 12/2008
4	Intravenous Administration 10/2022 - 12/2008
4	Immunotherapy 10/2021 - 09/2016
3	Cell Transplantation 01/2020 - 02/2015
3	Homologous Transplantation 01/2019 - 04/2015
3	Radioimmunotherapy 01/2017 - 06/2012